# A Study of Camrelizumab Combined Apatinib in Hepatocellular Carcinoma Previously Treated With Immune Checkpoint Inhibitors (ICIs).

> **NCT04826406** · PHASE2 · UNKNOWN · sponsor: **Hunan Cancer Hospital** · enrollment: 40 (estimated)

## Conditions studied

- Hepatocellular Carcinoma
- Immune Checkpoint Inhibitors

## Interventions

- **DRUG:** Camrelizumab combined Apatinib regimen

## Key facts

- **NCT ID:** NCT04826406
- **Lead sponsor:** Hunan Cancer Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-02-03
- **Primary completion:** 2022-03-02
- **Final completion:** 2023-08-30
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2021-04-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04826406

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04826406, "A Study of Camrelizumab Combined Apatinib in Hepatocellular Carcinoma Previously Treated With Immune Checkpoint Inhibitors (ICIs).". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04826406. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*